KORU Medical Systems, Inc.
NASDAQ:KRMDMedical - Instruments & Supplies
+$0.06 today
- Market cap
- $149.64M
- Beta
- 0.42
- P/E (TTM)
- -80.2
- EPS (TTM)
- -$0.05
Volume 0.19M
Average 0.13M
KRMD Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
KORU Medical Systems, Inc.NASDAQ: KRMD
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $8.77M at the end of Q1 FY2026, up 0.4% from a year earlier and down 1.2% from the prior quarter. Over 3 fiscal years it compounded at -20.1% a year.
Context
- Cash & equivalents amounted to 30.7% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +0.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 8.87M USD
- Year-over-year change
- -7.4%
- 4-year CAGR
- -23.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.87M | -7.4% |
| FY2024 | 2024-12-31 | 9.58M | -16.6% |
| FY2023 | 2023-12-31 | 11.48M | -34.0% |
| FY2022 | 2022-12-31 | 17.41M | -31.3% |
| FY2021 | 2021-12-31 | 25.33M | — |
Cash & Equivalents vs competitors
How KRMD compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.4% is the 6th highest of 10, against a peer median of +4.9%.
- Cash & equivalents amounts to 30.7% of total assets for KRMD, versus a peer median of 32.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $176.96M USD | -28.5% | +33.4% | 46.7% | |
| Mar 2026 | $87.41M USD | +4.9% | +4.5% | 70.3% | |
| Mar 2026 | $56.55M USD | +335.0% | +29.5% | 79.7% | |
| Mar 2026 | $56.02M USD | +16.8% | -39.7% | 32.0% | |
| Mar 2026 | $50.46M USD | +8.7% | +20.7% | 68.5% | |
| Mar 2026 | $14.56M USD | -37.8% | +21.9% | 7.5% | |
| Mar 2026 | $13.21M USD | -37.7% | -21.4% | 10.5% | |
| Mar 2026 | €12.98M EUR | -42.0% | +18.8% | 13.3% | |
| Mar 2026 | $8.77M USD | +0.4% | -20.1% | 30.7% | |
| Mar 2026 | $2.11M USD | +39.8% | +168.3% | 2.1% | |
| Peer median (excluding KRMD) | — | +4.9% | +20.7% | 32.0% | |
Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.33M | 17.41M | 11.48M | 9.58M | 8.87M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 3.59M | 3.56M | 4.05M | 6M | 6.53M |
| Inventory | 6.11M | 6.4M | 3.48M | 2.8M | 3.68M |
| Other Current Assets | 718.22K | 972.4K | 28.89K | 749.85K | 908.54K |
| Total Current Assets | 37.32M | 29.8M | 20.26M | 19.13M | 19.99M |
| Property, Plant & Equipment (Net) | 1.2M | 7.67M | 7.35M | 7.26M | 7.43M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 808.81K | 787.18K | 754.36K | 730.28K | 684.84K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.96M | 4.07M | 98.97K | 98.97K | 98.97K |
| Total Non-current Assets | 3.97M | 12.53M | 8.21M | 8.09M | 8.21M |
| Total Assets | 41.29M | 42.33M | 28.46M | 27.22M | 28.2M |
| Account Payables | 1.23M | 2.39M | 975.19K | 1.65M | 2.27M |
| Short-term Debt | 508.58K | 433.3K | 314.34K | 271.15K | 538.36K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 90K | 257.34K | 512.52K | 29.27K | 5.39M |
| Total Current Liabilities | 4.79M | 6.96M | 4.45M | 7.2M | 8.19M |
| Long-term Debt | 0 | 0 | 0 | 0 | 2.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 1 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 4.05M | 3.65M | 3.2M | 2.96M |
| Total Liabilities | 4.79M | 11.01M | 8.11M | 10.4M | 11.15M |
| Common Stock | 480.44K | 488.62K | 490.9K | 493.78K | 497.91K |
| Retained Earnings | (910.07K) | (9.57M) | (23.31M) | (29.38M) | (32.02M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | (0) | (0) | (0) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 36.5M | 31.33M | 20.35M | 16.81M | 17.05M |
| Total Debt | 604.14K | 4.93M | 4.45M | 3.99M | 3.5M |
| Net Debt | (24.73M) | (12.48M) | (7.04M) | (5.59M) | (5.38M) |
KORU Medical Systems, Inc.
NASDAQ:KRMD
Intrinsic Alpha fair value
Locked
Current Price
$3.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.